Researchers find metabolic mechanism that blocks immune response, immunotherapy in cancer

Novel finding suggests a possible target for improving response to immune-based cancer treatments

11:00 AM

Author | Nicole Fawcett

close up of orange and purple squiggle-looking cells merging and a little green in the middle
Credit: Heng Lin, Michigan Medicine

The immune system is a major target for cancer treatments. 

Immune checkpoint inhibitors and CAR-T cell therapy can dramatically improve outcomes for many cancers. 

But for about 70% of patients, these therapies don’t work.

Researchers at the University of Michigan Health Rogel Cancer Center have discovered a key reason why some cancers don’t respond to immunotherapy: A metabolite transporter within the tumor microenvironment that blocks a key type of tumor cell death integral to immune response.

“Tumor cells adapt their metabolic mechanisms to evade immune-base therapies. Understanding how these mechanisms of immune resistance work can provide new targets to refine immune-based treatments so they benefit more patients. Our discovery is one step in that direction,” said senior study author Weiping Zou, M.D., Ph.D., director of the Center of Excellence for Cancer Immunology and Immunotherapy at the Rogel Cancer Center.

Researchers identified SLC13A3 as a transporter of the metabolite itaconate in tumor cells that causes the cell to be resistant to ferroptosis, a form of regulated cell death. 

Zou and colleagues were first to report that immune-regulated ferroptosis occurs in tumor cells and plays a key role in cancer immunotherapy, in two previous papers.

In the study, published in Cancer Cell, researchers found that high levels of SLC13A3 in patient tumor samples was associated with poor response to immunotherapy and poor overall survival in patients. 

They tested this in tumor samples from patients with multiple cancer types from multiple institutions. 

Researchers then validated the findings in tumor bearing mouse models in which tumor SLC13A3 was knocked out. 

Deleting SLC13A3 led to reduced tumor development and progression, while restoring SLC13A3 caused tumor progression.

They also noted increased immune cells in the mice when tumor SLC13A3 was deleted, compared to those expressing SLC13A3.

Going a step further, researchers uncovered the mechanism driving this: tumor cells use SLC13A3 to uptake a metabolite called itaconate. 

Then, itaconate stimulates a ferroptosis resistant mechanism and makes tumor cells resistant to ferroptotic cell death, thereby becoming unresponsive to immunotherapy. 

Itaconate is produced by macrophages in the tumor microenvironment, which means there exists a detrimental crosstalk between macrophages and tumor cells via SLC13A3.

SEE ALSO: Researchers find new target to improve response to cancer immunotherapy

In collaboration with Shaomeng Wang, M.D., Ph.D., and team, researchers created a structural model of SLC13A3 to screen and identify a potential inhibitor, SLC13A3i, that could prevent tumor cells from taking up itaconate and reverse ferroptosis resistance. 

They tested this inhibitor in mice as a single therapy and in combination with an immune checkpoint inhibitor. 

The SLC13A3 inhibitor alone reversed the ferroptosis resistance and treated cancers in mice. 

In combination, the two inhibitors blocked tumor progression and bolstered the effectiveness of the immune-based treatment in mice.

“Our studies show SLC13A3 plays a key role in shaping the fate of tumor cells and the effectiveness of immune-based cancer treatments. SLC13A3 is a promising target for developing clinically applicable SLC13A3 inhibitors that could make immune-based therapies more effective for more patients,” Zou said.

Additional authors: Heng Lin, Kole Tison, Yuheng Du, Paul Kirchhoff, Chan Kim, Weichao Wang, Hannah Yang, Michael Pitter, Jiali Yu, Peng Liao, Jiajia Zhou, Linda Vatan, Sara Grove, Shuang Wei, Thomas Vigil, Yatrik M. Shah, Richard Mortensen, Ilona Kryczek, Lana Garmire, Jwala P. Sivaccumar, Ashwin Kumar Ramesh, Ningyan Zhang and Zhiqiang An.

Funding: National Cancer Institute grants CA248430, CA217648, CA123088, CA099985, CA193136, CA152470, R01CA148828, P30CA46592 and the Welch Foundation.

Disclosure: Zhang, An, Sivaccumar, Ramesh, Zou, Lin, Wang and Kirchhoff are listed inventors in a patent application related to this work.

Paper cited: “Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance,” Cancer Cell. DOI: 10.1016/j.ccell.2024.10.010

Sign up for Health Lab newsletters todayGet medical tips from top experts and learn about new scientific discoveries every week.

Sign up for the Health Lab PodcastAdd us wherever you listen to your favorite shows. 


More Articles About: All Research Topics Basic Science and Laboratory Research Cancer: Help, Diagnosis & Treatment Cancer Research
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

In This Story
zou weiping Weiping Zou

Professor

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories cancer cell
Health Lab
Artificial intelligence predicts genetics of cancerous brain tumors in under 90 seconds
A new study finds AI-based diagnostic screening system, DeepGlioma, detects genetic mutations in brain tumors in under 90 seconds. Streamlining glioma diagnosis and treatment.
brain drawn
Health Lab
The brain in balance
In a recent study, using network neuroscience, investigators found a way to objectively determine the balance of integration and segregation in fMRI-measured brain signals during wakefulness as well as during sleep and anesthesia.
yellow blue maroon close up image of cells
Health Lab
A newly developed algorithm shows how a gene is expressed at microscopic resolution
Seeing is believing: A newly developed algorithm allows researchers to see how a gene is expressed at microscopic resolution.
Susan and Richard Rogel pose next to a grand piano. Rogel is wearing a polo shirt with a block M.
News Release
Rogel Cancer Center receives $50M gift to revolutionize pancreatic cancer care, research
New Rogel and Blondy Center for Pancreatic Cancer will bring together researchers and clinicians to drive forward new treatments and improve outcomes
doctors talking to eachother down a hallway
Health Lab
A collaborative approach to pancreatic cancer
The Rogel and Blondy Center for Pancreatic Cancer is a center of excellence in pancreatic cancer research, combining pioneering research with innovative clinical care and an array of clinical trials. Center co-director Marina Pasca di Magliano explains that the key to a robust research program and responsive care lies in collaboration.
doctor with head and neck in hands sitting down seeming depressed or stressed
Health Lab
More research is needed to support physicians' mental health, experts say
A pair of researchers who have studied physician mental health and stress call for more efforts to supports to prevent burnout and support wellbeing.